Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
AssigneeBoard of Regents, The University of Texas System
InventorsJacqulyne Robichaux, Monique Nilsson, John V. Heymach
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.
Claims18
A method of treating cancer in a subject comprising administering an effective amount of poziotinib to the subject, wherein the subject has a tumor that has been determined to have one or more EGFR exon 20 insertion mutations, wherein the mutations comprise an insertion of 1-6 amino acids between amino acids 763-778.
Dependencies are inferred from the claim text.